Regeneron Pharmaceuticals (REGN) investor relations material

Strategic Overview and Innovation

• Emphasizes a science-first, big data-driven approach, integrating genetics, proteomics, and proprietary platforms like VelocImmune and the Regeneron Genetics Center to accelerate drug discovery and development.

• Maintains a robust pipeline with 45 clinical candidates across six therapeutic areas and 14 approved therapies, reflecting a commitment to addressing unmet medical needs and supporting future growth.

• Focuses R&D investment primarily on internal innovation, with about 95% of resources dedicated to in-house projects, citing higher returns and sustainability compared to external deals.

• Plans to invest approximately $6 billion in R&D and over $7 billion in US capital investments in the coming years, with disciplined capital allocation.

• Returned $3.8 billion to shareholders in 2025 through buybacks and dividends, and initiated a quarterly dividend that year.

Key Product and Franchise Updates

• Eylea HD net sales in Q4 2025 reached $506 million in the US, up 66% year-over-year, with label expansions and a growing share of franchise sales.

• Dupixent, co-commercialized with Sanofi, is the most widely used branded antibody globally, with over 1.3 million patients and annualized global net sales exceeding $19 billion.

• Libtayo is the only approved IO treatment for adjuvant CSCC in the US and is gaining share in advanced lung cancer, with a strong commercial outlook.

• Key programs include Eylea HD, Dupixent, Libtayo, Lynozyfic, Ordspono, and multiple investigational therapies in advanced clinical stages.

• Foundation contributions and matching funds are supporting efforts to counter biosimilar competition and improve patient access.

Pipeline and Clinical Development Highlights

• Advancing a broad pipeline including antibodies, bispecifics, siRNAs, gene therapies, CAR T, peptides, and gene editing, with multiple late-stage programs set for data readouts in 2024–2026.

• Immunology and inflammation franchise is developing long-acting IL4R alpha, IL13, and IL4 antibodies, with expedited clinical plans for IL-13 and next-gen approaches focusing on longer dosing intervals and allergen-specific therapies.

• Novel allergy treatments are in development, including approaches to eliminate IgE-driven allergies, with proof of principle achieved in early patients.

• Linvoseltamab (Lynozyfic), a BCMAxCD3 bispecific, showed 100% MRD negativity in first-line multiple myeloma and precursor conditions, with several registrational studies underway.

• Complement inhibition program (Cemdisiran and Pozelimab) demonstrated superior LDH control in PNH and positive phase 3 results in myasthenia gravis, with regulatory submissions planned for 2026.